Aesculus Hippocastanum Extract and the Main Bioactive Constituent β-escin As Antivirals Agents Against Coronaviruses, Including SARS-CoV-2

Overview

Journal Sci Rep

Specialty Science

Date 2024 Mar 18

PMID 38494515

Authors

Freddy Armando Penaranda Figueredo

Josefina Vicente

Andrea Alejandra Barquero

Carlos Alberto Bueno

Affiliations

Soon will be listed here.

Abstract

Respiratory viruses can cause life-threatening illnesses. The focus of treatment is on supportive therapies and direct antivirals. However, antivirals may cause resistance by exerting selective pressure. Modulating the host response has emerged as a viable therapeutic approach for treating respiratory infections. Additionally, considering the probable future respiratory virus outbreaks emphasizes the need for broad-spectrum therapies to be prepared for the next pandemics. One of the principal bioactive constituents found in the seed extract of Aesculus hippocastanum L. (AH) is β-escin. The clinical therapeutic role of β-escin and AH has been associated with their anti-inflammatory effects. Regarding their mechanism of action, we and others have shown that β-escin and AH affect NF-κB signaling. Furthermore, we have reported the virucidal and broad-spectrum antiviral properties of β-escin and AH against enveloped viruses such as RSV, in vitro and in vivo. In this study, we demonstrate that β-escin and AH have antiviral and virucidal activities against SARS-CoV-2 and CCoV, revealing broad-spectrum antiviral activity against coronaviruses. Likewise, they exhibited NF-κB and cytokine modulating activities in epithelial and macrophage cell lines infected with coronaviruses in vitro. Hence, β-escin and AH are promising broad-spectrum antiviral, immunomodulatory, and virucidal drugs against coronaviruses and respiratory viruses, including SARS-CoV-2.

References

Latreille E, Lee W . Modulation of the Host Response as a Therapeutic Strategy in Severe Lung Infections. Viruses. 2023; 15(7). PMC: 10386155. DOI: 10.3390/v15071462. View

Smyk J, Szydlowska N, Szulc W, Majewska A . Evolution of Influenza Viruses-Drug Resistance, Treatment Options, and Prospects. Int J Mol Sci. 2022; 23(20). PMC: 9602850. DOI: 10.3390/ijms232012244. View

Sirtori C . Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001; 44(3):183-93. DOI: 10.1006/phrs.2001.0847. View

Pittler M, Ernst E . Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012; 11:CD003230. PMC: 7144685. DOI: 10.1002/14651858.CD003230.pub4. View

Domanski D, Zegrocka-Stendel O, Perzanowska A, Dutkiewicz M, Kowalewska M, Grabowska I . Molecular Mechanism for Cellular Response to β-Escin and Its Therapeutic Implications. PLoS One. 2016; 11(10):e0164365. PMC: 5058498. DOI: 10.1371/journal.pone.0164365. View

Michelini F, Alche L, Bueno C . Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hippocastanum extract. J Pharm Pharmacol. 2018; 70(11):1561-1571. DOI: 10.1111/jphp.13002. View

Salinas F, Vazquez L, Gentilini M, O Donohoe A, Regueira E, Nabaes Jodar M . Aesculus hippocastanum L. seed extract shows virucidal and antiviral activities against respiratory syncytial virus (RSV) and reduces lung inflammation in vivo. Antiviral Res. 2019; 164:1-11. DOI: 10.1016/j.antiviral.2019.01.018. View

Vicente J, Benedetti M, Martelliti P, Vazquez L, Gentilini M, Penaranda Figueredo F . The Flavonoid Cyanidin Shows Immunomodulatory and Broad-Spectrum Antiviral Properties, Including SARS-CoV-2. Viruses. 2023; 15(4). PMC: 10143848. DOI: 10.3390/v15040989. View

Nilsson-Payant B, Uhl S, Grimont A, Doane A, Cohen P, Patel R . The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication. J Virol. 2021; 95(23):e0125721. PMC: 8577386. DOI: 10.1128/JVI.01257-21. View

10.

Milani D, Caruso L, Zauli E, Al Owaifeer A, Secchiero P, Zauli G . p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics). Front Pharmacol. 2022; 13:871583. PMC: 9201997. DOI: 10.3389/fphar.2022.871583. View

11.

Poppe M, Wittig S, Jurida L, Bartkuhn M, Wilhelm J, Muller H . The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 2017; 13(3):e1006286. PMC: 5386326. DOI: 10.1371/journal.ppat.1006286. View

12.

Huang H, Wang S, Fang G, Chou W, Liao C, Sun C . Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. J Med Virol. 2023; 95(2):e28478. PMC: 10107526. DOI: 10.1002/jmv.28478. View

13.

Lacasse E, Gudimard L, Dubuc I, Gravel A, Allaeys I, Boilard E . SARS-CoV-2 Nsp2 Contributes to Inflammation by Activating NF-κB. Viruses. 2023; 15(2). PMC: 9964531. DOI: 10.3390/v15020334. View

14.

Gudowska-Sawczuk M, Mroczko B . The Role of Nuclear Factor Kappa B (NF-κB) in Development and Treatment of COVID-19: Review. Int J Mol Sci. 2022; 23(9). PMC: 9101079. DOI: 10.3390/ijms23095283. View

15.

Li T, Kenney A, Park J, Fiches G, Liu H, Zhou D . SARS-CoV-2 Nsp14 protein associates with IMPDH2 and activates NF-κB signaling. Front Immunol. 2022; 13:1007089. PMC: 9513374. DOI: 10.3389/fimmu.2022.1007089. View

16.

Salinas F, Diaz Nebreda A, Vazquez L, Gentilini M, Marini V, Benedetti M . Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs. Antiviral Res. 2020; 179:104817. PMC: 7202858. DOI: 10.1016/j.antiviral.2020.104817. View

17.

Edwards A, Baric R, Saphire E, Ulmer J . Stopping pandemics before they start: Lessons learned from SARS-CoV-2. Science. 2022; 375(6585):1133-1139. DOI: 10.1126/science.abn1900. View

18.

Okomo U, Idoko O, Kampmann B . The burden of viral respiratory infections in young children in low-resource settings. Lancet Glob Health. 2020; 8(4):e454-e455. DOI: 10.1016/S2214-109X(20)30037-1. View

19.

Watson A, Wilkinson T . Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021; 15:1753466621995050. PMC: 7989115. DOI: 10.1177/1753466621995050. View

20.

Cohen M . Early treatment to prevent progression of SARS-CoV-2 infection. Lancet Respir Med. 2022; 10(10):930-931. PMC: 9173720. DOI: 10.1016/S2213-2600(22)00213-2. View